Nanolek LLC informs about changes in the ownership structure: K2 Group, previously holding a 50% of the company, has divested its interest, transferring it equally to private entrepreneurs Gennady Schweigert and Pavel Mileiko. The transaction will have no impact on the company’s business strategy, operational processes and the relationships with partners and counterparties.
The change in ownership of Nanolek LLC, effective 14 January 2025 reflects company’s continued development in the prevention and treatment of socially significant diseases. The new partners bring extensive expertise in pharmaceutical business development and healthcare projects, significantly contributing to the company’s strategic goals.
Nanolek LLC operates withing the budget-funded pharmaceuticals market, aligning its development with the state healthcare and pharmaceutical policies, including the Strategy for the Development of the Pharmaceutical Industry of the Russian Federation until 2030 (‘Pharma 2030’). The long-term, capital-intensive nature of its projects ensures that existing plans will remain unaffected. As before the change in ownership Nanolek’s priorities remain strengthening its market position and building a diversified portfolio of drugs for the prevention and treatment of socially significant diseases.
A key area is vaccine production. Nanolek is the leading supplier of pediatric vaccines in Russia, focused on expanding production capacity and developing new vaccine candidates for inclusion in the national immunization calendar under Pharma 2030. Other strategic goals include developing portfolio of orphan drugs and specialized therapies to meet high healthcare demand.
Nanolek currently offers 7 vaccines and 15 specialized therapy drugs. In 2024, 22 of its products participated in government tenders totaling over RUB 27 billion. 58% of this volume accounted for federal tenders (23 auctions in 88 regions), 12% for regional tenders (193 auctions in 55 regions), and the remaining share for sales to 49 distributors. Nanolek’s sales and medical representatives cover all regions of the Russian Federation.
Nanolek actively contributes to the consolidation of the pharmaceutical industry, being a member of the Association of Pharmaceuticals of the EAEU and sharing its expertise with industry leaders. The company’s mission – ‘to protect life and health, making the world’s best global technologies accessible to everyone’ is realized through effective cooperation with foreign and domestic partners, research organisations and universities.
Nanolek’s senior management team comprises executives with at least 5 years of tenure, deeply committed to the company’s strategic vision and immersed in the industry’s regulatory landscape. In particular, CEO Evgeny Barinov has been with the company for over 11 years, playing a pivotal role in its development as a leading manufacturer of pediatric vaccines. He previously served as a Board member and Deputy CEO for Finance and Digital Technologies. As CEO, Mr. Barinov is to ensure in achieving long-term goals and securing Nanolek’s position as a major independent industry player, contributing to the accessibility of drug therapies for the prevention and treatment of socially significant diseases. Under his leadership the company’s operational activities are centered on expanding production capacity, enhancing financial management and systematically implementing innovative digital technologies.
Nanolek LLC operates on principles of fair competition, market intelligence, constant pursuit of effective tools to maintain industry leadership and fostering strong partnerships. These principles and priorities will remain unchanged following recent changes in the company’s ownership structure.
